Syneos Health is evolving its patient recruitment capabilities to further address unmet sponsor, site and patient needs. Through its collaboration with the...
The bridging study is a multicenter, open-label, Phase II study to evaluate the efficacy, safety and pharmacokinetics of tazemetostat for the treatment of ...
Results show 26 weeks of treatment with twice-daily 60 mg dose of BMS-986278 resulted in a 69% relative reduction in the rate of decline in percent predict...
– Results Show Encouraging Activity of Trodelvy in Combination with KEYTRUDA in 1L Metastatic NSCLC Across all PD-L1 Subgroups and Histologies Studie...
Cell BioEngines, Inc. is strengthening its Intellectual Property portfolio with a patent licensed from the Icahn School of Medicine at Mount Sinai, in New ...
US-based startup Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialise ob...
Neurophet, an artificial intelligence (AI) solution company for brain disease, announced its participation in the global startup innovation program 'Startu...
The aim of the LOVE-DEB Study (Large de-NOVo coronary artEry disease treated with sirolimus Drug Eluting Balloon: prospective evaluation of safety & ef...
eClinicalWorks®, the largest ambulatory cloud EHR, today announced the recent successes of Innova Primary Care (Innova), a full-service primary care pr...
ISA Pharmaceuticals B.V., a clinical-stage biotech company developing immunotherapies to treat cancers and serious infectious diseases, is pleased to ...
Designations for Daiichi Sankyo and AstraZeneca's ENHERTU include patients with HER2 expressing metastatic solid tumors and HER2 positive metastatic colo...
The study is a randomized, double-blind Phase Ib study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of APL-1401 in patie...
OMTX705 is a novel antibody–drug conjugate (ADC) molecule targeting fibroblast-activating protein α (FAPα). FAPα is a dimeric type ...
These models are essential for testing in vivo efficacy of novel therapeutics against lung cancer, elevating the prospects for significant advances in the ...
© 2025 Biopharma Boardroom. All Rights Reserved.
